Under construction – not a live service
Sign in
Taking people in NetherlandsNo phase

AI-assisted heart tracing tests for chest pain without blocked arteries

Tests AI-assisted heart rhythm recordings to detect chest pain caused by coronary artery problems.

Key facts

Who runs it
UMC Utrecht
Where
Utrecht, NetherlandsSee the site
Trial code
Registry title
Artificial Intelligence in ANOCA
Status
Recruiting
People taking part
250 people, planned
Started
3 Dec 2024
Expected to end
Dec 2028
Type of study
Interventional
Treatments tested
  • Holter monitoring, intracoronary ECG
Record updated
12 January 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with ongoing chest discomfort who have no blocked heart arteries needing a procedure. They are having a coronary function test.

Age
18 years and older
Sex
All sexes can join
Disease stage
Chest discomfort (angina) at least 2 times per week despite current medicine, with no obstructive coronary artery disease that needs revascularization, shown on a recent CCTA scan or invasive coronary angiography
Earlier treatment
Must still have chest discomfort despite current medical therapy

Main reasons for not taking part

  • No chest discomfort after starting medical therapy
  • Language barrier that prevents enough understanding and communication in Dutch

The registry criteria, word for word

Show all 5 criteriaShow less

Who can take part

  • Clinical indication for comprehensive coronary function testing because of persisting chest discomfort at least 2 times per week despite current medical therapy
  • Absence of obstructive coronary artery disease with an indication for revascularization, documented by means of recent coronary computed tomography angiography (CCTA) or invasive coronary angiography (with invasive coronary pressure measurements if clinically indicated)
  • Patient is willing and able to provide written informed consent

Who cannot take part

  • Absence of chest discomfort after initiation of medical therapy
  • Language barrier preventing sufficient understanding and communication in Dutch

Where in Netherlands

  • UMC UtrechtUtrecht, NetherlandsContact: Tim P. van de Hoef, M.D., Ph.D.Taking people

About the trial

What the trial wants to find out

Angina pectoris is diagnosed in >180.000 people in the Netherlands each year. Diagnosis in angina pectoris focuses on epicardial coronary stenosis, the identification of which may lead to guideline-directed medical therapy or revascularization. However, no such stenosis is identified in 40-70% of patients. This condition, angina with no obstructed coronary artery (ANOCA), is more prevalent in women and is related to poor quality of life, high medical expenses, and a higher incidence of adverse events.

Read full original descriptionShow less

The origin of ANOCA can be evaluated during invasive coronary angiography by coronary function testing (CFT) to identify coronary vasomotor disorders. This relates to vasospasm of the coronary artery and microcirculation, or to impaired microvascular vasodilation. For the diagnosis of vasospasm, CFT needs to result in electrocardiographic signs of myocardial ischemia as part of the diagnostic criteria. This is a critical point in the diagnosis of vasospasm, as these signs can be subtle and can vary, and are therefore prone to misinterpretation. Apart from this caveat, the diagnosis approach therefore currently requires an invasive procedure for the diagnosis. This limits the broad application and hampers early identification and treatment of ANOCA.

During CFT, a coronary guide wire is routinely advanced in the coronary artery which also allows obtaining an intracoronary ECG by attaching a sterile alligator clamp to a standard electrocardiogram lead. This allows continuous recording of intracoronary ECG throughout CFT on the same monitor as the routine ECG. This technique can increase sensitivity for myocardial ischemia during CFT. Further, Holter ECG monitoring allows the identification of ischemic changes in the ECG in the outpatient setting. Evidence is lacking on the patterns of myocardial ischemia that occur during spontaneous angina pectoris symptoms in ANOCA patients, and on the sensitivity of Holter ECG for this purpose. Finally, the interpretation of ischemic patterns on ECG tracings can be cumbersome, especially when changes are subtle or change from beat to beat. The use of deep learning techniques allows to automate the interpretation of ECG traces and may improve the standardized diagnosis in ANOCA.

The group in the trial

  • Single armTreatment being tested

    Intracoronary ECG and Holter ECG monitoring

    Treatment: Holter monitoring, intracoronary ECG

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Artificial Intelligence-assisted Diagnostics In Angina With No Obstructive Coronary Artery Disease
Plain-language title
AI-assisted heart tracing tests for chest pain without blocked arteriesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
12 January 2026